JP2018522045A - Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節 - Google Patents

Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節 Download PDF

Info

Publication number
JP2018522045A
JP2018522045A JP2018505665A JP2018505665A JP2018522045A JP 2018522045 A JP2018522045 A JP 2018522045A JP 2018505665 A JP2018505665 A JP 2018505665A JP 2018505665 A JP2018505665 A JP 2018505665A JP 2018522045 A JP2018522045 A JP 2018522045A
Authority
JP
Japan
Prior art keywords
cancer
cells
tumor
ezh2
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018505665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522045A5 (enExample
Inventor
ゴーシュ，スリモイー
ローラ，ジョセ・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Constellation Pharmaceuticals Inc
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of JP2018522045A publication Critical patent/JP2018522045A/ja
Publication of JP2018522045A5 publication Critical patent/JP2018522045A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018505665A 2015-08-03 2016-07-28 Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節 Pending JP2018522045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200244P 2015-08-03 2015-08-03
US62/200,244 2015-08-03
PCT/US2016/044409 WO2017023671A1 (en) 2015-08-03 2016-07-28 Ezh2 inhibitors and modulation of regulatory t-cell function

Publications (2)

Publication Number Publication Date
JP2018522045A true JP2018522045A (ja) 2018-08-09
JP2018522045A5 JP2018522045A5 (enExample) 2019-09-12

Family

ID=56611618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018505665A Pending JP2018522045A (ja) 2015-08-03 2016-07-28 Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節

Country Status (8)

Country Link
US (1) US20180221362A1 (enExample)
EP (1) EP3331561A1 (enExample)
JP (1) JP2018522045A (enExample)
CN (1) CN108136011A (enExample)
AU (1) AU2016302747A1 (enExample)
CA (1) CA2994394A1 (enExample)
HK (1) HK1256604A1 (enExample)
WO (1) WO2017023671A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517491A (ja) * 2016-06-01 2019-06-24 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018275123A1 (en) * 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
WO2020063863A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
CN112007162B (zh) * 2019-05-30 2023-05-12 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN114040776B (zh) * 2019-06-28 2024-05-14 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
MD4003532T2 (ro) 2019-07-24 2025-01-31 Constellation Pharmaceuticals Inc Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
PH12022550189A1 (en) * 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Ezh2 inhibition in combination therapies for the treatment of cancers
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
WO2023108563A1 (zh) * 2021-12-16 2023-06-22 北京大学第三医院（北京大学第三临床医学院） 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
WO2024106878A1 (ko) * 2022-11-17 2024-05-23 인제대학교 산학협력단 Ezh2 저해제 및 항-pd-1 항체를 포함하는, 암의 예방 또는 치료용 약제학적 조성물
WO2025085536A1 (en) * 2023-10-16 2025-04-24 Lankenau Institute For Medical Research Biologic conjugates that inhibit production of inflammatory cells and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530753A (ja) * 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
JP2013527173A (ja) * 2010-05-07 2013-06-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー アザインダゾール
WO2014124418A1 (en) * 2013-02-11 2014-08-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013005806B1 (pt) * 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
CA2854447A1 (en) * 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
CN103690531A (zh) * 2012-09-27 2014-04-02 烟台大学 茶乙香酸等在制备具有预防和治疗癌症等疾病的产品中的应用
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530753A (ja) * 2007-06-18 2010-09-16 エン． フェー． オルガノン ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
JP2013527173A (ja) * 2010-05-07 2013-06-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー アザインダゾール
WO2014124418A1 (en) * 2013-02-11 2014-08-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOMURA, T. ET AL., CURR TOP MICROBIOL IMMUNOL, vol. 293, JPN6020033231, 2005, pages 287 - 302, ISSN: 0004496516 *
WANG, J. ET AL., J HEMATOL ONCOL, vol. 4, no. 50, JPN6020033227, 2011, pages 1 - 10, ISSN: 0004496515 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517491A (ja) * 2016-06-01 2019-06-24 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
JP7121660B2 (ja) 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用

Also Published As

Publication number Publication date
CN108136011A (zh) 2018-06-08
HK1256604A1 (zh) 2019-09-27
CA2994394A1 (en) 2017-02-09
US20180221362A1 (en) 2018-08-09
WO2017023671A1 (en) 2017-02-09
AU2016302747A1 (en) 2018-02-22
EP3331561A1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
JP2018522045A (ja) Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節
Fan et al. A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy
Huang et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells
US20160215042A1 (en) Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
AU2015287969B2 (en) Methods of treating cancer
EP3532606A1 (en) Immunosuppressive mesenchymal cells and methods for forming same
WO2017096274A1 (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
JP2018529753A (ja) 転移性及び難治性癌及び腫瘍の処置のための方法及び組成物
CN108883179A (zh) 组蛋白脱乙酰酶抑制剂用于增强免疫治疗的用途
AU2018344001A1 (en) Immunogenic composition for the treatment of cancer
Wanhainen et al. P2RX7 enhances tumor control by CD8+ T cells in adoptive cell therapy
WO2016168264A1 (en) Methods and compositions for treating cancer with dendritic cells
Hu et al. Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model
Kim et al. Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses
JP2022502433A (ja) 治療方法
KR102352127B1 (ko) Mitf 억제제를 유효성분으로 함유하는 골수-유래 억제세포 저해용 조성물
Peng et al. Combination of Hdac Inhibitor Sodium Butyrate and Immunotherapy in Glioma: Regulation of Immunologically Hot and Cold Tumors Via Gut Microbiota and Metabolites
Singh et al. Extracellular vesicle-derived miRNA-182-5p educates macrophages towards an immunosuppressive phenotype in pancreatic cancer
US20250144107A1 (en) Use of a pikfyve inhibitor in combination with immunotherapy
Dou et al. Reconstituted CD74+ NK cells trigger chronic graft versus host disease after allogeneic bone marrow transplantation
Lee The role of innate immunity in pancreatic cancer progression and treatment
Zhai et al. Bortezomib Enhances CD70 CAR-T Cell Therapy in Sunitinib Resistant Renal Cell Carcinoma by Inducing Mitochondrial DNA Mediated cGAS-STING Activation
Scirocchi Immune receptor CD137 as a biomarker in solid tumors and potential immunotherapeutic target in glioblastoma
WO2024063109A1 (ja) 老化細胞除去剤
KR20230074195A (ko) 조혈 세포 이식 후에 혈액학적 신생물 재발의 치료 또는 예방에 사용하기 위한 mdm2 억제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210428